Home › NCT03225820

Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients must be at least 18 years of age.
* Patients must self-identify as African American

Exclusion Criteria:

* Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
* Patients with known active or prior leukemia.
* Inability to understand and give informed consent to participate.
* For patients being recruited to the warfarin sub-study, those with a glomerular filtration rate or creatinine clearance \<30 mL/min34.

About the study

(a) To explore the feasibility and utility of implementing broad preemptive pharmacogenomic result delivery in the inpatient setting across multiple institutions specifically with the goal of incorporating minority-specific pharmacogenomic information; (b) To determine whether clinical outcomes for the drug warfarin are improved in African Americans through the availability of pharmacogenomics-based dosing guidance at the point-of-care.

Sponsor: University of Chicago · Participants: 1,000 · Started: Nov 9, 2017

Contact the study team

• Cancer Clinical Trials Office · Phone: 1-855-702-8222

Official record on ClinicalTrials.gov — NCT03225820

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.